Business
OncBioMune Protects ProscaVax Cancer Treatment Technology in Hong Kong
OncBioMune Protects ProscaVax Cancer Treatment Technology in Hong Kong.
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\nOncBioMune Protects ProscaVax Cancer Treatment Technology in Hong Kong\n\nOncBioMune Protects ProscaVax Cancer Treatment Technology in Hong Kong\n\nBATON ROUGE, LA--(Marketwired - June 07, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (\"OncBioMune\" or the \"Company\"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies and a proprietary vaccine technology and commercialization of a portfolio of products internationally, today announces that patent No. 14101607.7 has been issued in Hong Kong covering ProscaVax, OncBioMune's novel immunotherapeutic cancer vaccine. The patent, titled, \"Composition and Method for Treating Cancer,\" protects ProscaVax in Hong Kong through January 8, 2032.ProscaVax is a clinical-stage protein therapeutic cancer vaccine combining tumor-associated antigens with biological adjuvants to selectively target tumor cells without damage to healthy cells. OncBioMune's intellectual property portfolio protecting ProscaVax and other technologies consists of 16 patents spanning approximately 50 countries worldwide.\"Prostate cancer is the third most common cancer in men in Hong Kong, accounting for approximately 11.3 percent of all newly diagnosed cancer cases in 2014,\" commented Andrew Kucharchuk, President and Chief Financial Officer at OncBioMune. \"We will remain vigilant in protecting our assets as part of our quest to bring effective, safe therapeutics to people in need in Hong Kong and globally.\"Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/. About OncBioMune Pharmaceuticals, Inc.OncBioMune Pharmaceuticals is a revenue-stage biopharmaceutical company engaged the development of novel cancer immunotherapy products, including a proprietary vaccine technology designed to stimulate the immune system to attack tumor cells without damaging healthy tissue. OncBioMune is also involved in drug development and commercialization internationally through our wholly-owned subsidiary, OncBioMune México, S.A. De C.V. Our lead pipeline product, ProscaVax™, is scheduled to commence two, separate mid-stage clinical trials in 2017: a Phase 2 for early-stage prostate cancer at a major Northwest U.S. university cancer research hospital and a Phase 2/3 study in Mexico for late-stage prostate cancer patients. OncBioMune has a portf...